A Phase II Study of Cabozantinib in Patients with Advanced Non-Small Cell Lung Cancer

Full Title

A Phase II Study of Cabozantinib in Patients with RET Fusion-Positive Advanced Non-Small Cell Lung Cancers

Purpose

KIF5B/RET is an abnormal gene that leads to the growth of lung cancer cells. Cabozantinib inhibits the effects of this gene. In addition, this drug interferes with other pathways that also cause cancer cells to grow, form new blood vessels, and spread to other parts of the body.

In this study, researchers are evaluating the safety and effectiveness of cabozantinib in patients with advanced non-small cell lung cancers that contain the KIF5B/RET gene. Cabozantinib is a pill that is taken orally (by mouth).

Protocol
12-097
Phase
Phase II (phase 2)
Investigator
Alexander Drilon
Diseases
Lung Cancer › Lung Cancer, Non-Small Cell
Lung Cancer, Non-Small Cell › Lung Adenocarcinoma
Thoracic › Lung Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT01639508
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description